Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers report details of new studies and findings in the area of cancer vaccines
February 8th, 2006
Cancer vaccines data are the focus of recent research from Germany, Australia and the South Korea. Study 1: B7-1 and B7-2 act differentially in the induction of a T cell response. According to recent research published in the International Journal of Cancer, "The efficacy of T cell-based immunotherapy is primarily due to efficient cellular activation that requires the engagement of two separate signals, i.e., via the T cell receptor complex and via costimulatory molecules the prototype of which is CD28. In cellular activation, the CD28 ligands B7-1 (CD80) and B7-2 (CD86) are thought to play nearly identical roles in T cell activation. We...
Source: Immunotherapy Weekly (2006-02-08)
|
